Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study investigating the pharmacokinetics, safety, and hormone concentrations of single and repeated administration of LF111 (drospirenone) in healthy Japanese women

Next Previous
Search
Trial Profile

A phase I/II study investigating the pharmacokinetics, safety, and hormone concentrations of single and repeated administration of LF111 (drospirenone) in healthy Japanese women

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Drospirenone (Primary)
  • Indications Pregnancy
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 24 Apr 2024 Planned initiation date changed from 18 Jan 2021 to NULL.
    • 23 Apr 2024 New trial record
    • 01 Apr 2024 Results evaluating the pharmacokinetics, pharmacodynamics, and safety of drospirenone as an oral contraceptive in Japanese women, published in the Journal of Obstetrics and Gynaecology Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top